The effect of intravenous hyoscine butylbromide on slow progress in labor (BUSCLAB): A double-blind randomized placebo-controlled trial
ConclusionsOne intravenous dose of 20 mg hyoscine butylbromide was not found to be superior to placebo in preventing slow labor progress in a population of first-time mothers at risk of prolonged labor. Further research is warranted to answer whether increased and/or repeated doses of hyoscine butylbromide might have an effect on duration of labor. Trial registrationClinicalTrials.gov (NCT03961165) EudraCT (2018-002338-19)
Source: PLoS Medicine - Category: Internal Medicine Authors: Lise Christine Gaudernack Source Type: research
More News: Chloride | Computers | Internal Medicine | International Medicine & Public Health | Norway Health | Perinatology & Neonatology | Sodium | Sodium Chloride | Statistics | Study | WHO | Women